Cargando…
S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428264/ http://dx.doi.org/10.1097/01.HS9.0000967388.89468.e9 |
| _version_ | 1785090426085048320 |
|---|---|
| author | Haddad, Fadi Jabbour, Elias Nasnas, Cedric Short, Nicholas Macaron, Walid Zoghbi, Marianne Nasr, Lewis Jain, Nitin Almanza, Emmanuel Sasaki, Koji Ravandi, Farhad Kebriaei, Partow Huang, Xuelin Garcia-Manero, Guillermo Kadia, Tapan Wang, Sa Jacob, Jovitta Garris, Rebecca O’brien, Susan Kantarjian, Hagop |
| author_facet | Haddad, Fadi Jabbour, Elias Nasnas, Cedric Short, Nicholas Macaron, Walid Zoghbi, Marianne Nasr, Lewis Jain, Nitin Almanza, Emmanuel Sasaki, Koji Ravandi, Farhad Kebriaei, Partow Huang, Xuelin Garcia-Manero, Guillermo Kadia, Tapan Wang, Sa Jacob, Jovitta Garris, Rebecca O’brien, Susan Kantarjian, Hagop |
| author_sort | Haddad, Fadi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428264 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104282642023-08-17 S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL Haddad, Fadi Jabbour, Elias Nasnas, Cedric Short, Nicholas Macaron, Walid Zoghbi, Marianne Nasr, Lewis Jain, Nitin Almanza, Emmanuel Sasaki, Koji Ravandi, Farhad Kebriaei, Partow Huang, Xuelin Garcia-Manero, Guillermo Kadia, Tapan Wang, Sa Jacob, Jovitta Garris, Rebecca O’brien, Susan Kantarjian, Hagop Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428264/ http://dx.doi.org/10.1097/01.HS9.0000967388.89468.e9 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Haddad, Fadi Jabbour, Elias Nasnas, Cedric Short, Nicholas Macaron, Walid Zoghbi, Marianne Nasr, Lewis Jain, Nitin Almanza, Emmanuel Sasaki, Koji Ravandi, Farhad Kebriaei, Partow Huang, Xuelin Garcia-Manero, Guillermo Kadia, Tapan Wang, Sa Jacob, Jovitta Garris, Rebecca O’brien, Susan Kantarjian, Hagop S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL |
| title | S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL |
| title_full | S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL |
| title_fullStr | S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL |
| title_full_unstemmed | S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL |
| title_short | S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL |
| title_sort | s119: combination of mini-hyper-cvd and inotuzumab (ino) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (all): a phase ii trial |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428264/ http://dx.doi.org/10.1097/01.HS9.0000967388.89468.e9 |
| work_keys_str_mv | AT haddadfadi s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT jabbourelias s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT nasnascedric s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT shortnicholas s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT macaronwalid s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT zoghbimarianne s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT nasrlewis s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT jainnitin s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT almanzaemmanuel s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT sasakikoji s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT ravandifarhad s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT kebriaeipartow s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT huangxuelin s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT garciamaneroguillermo s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT kadiatapan s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT wangsa s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT jacobjovitta s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT garrisrebecca s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT obriensusan s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial AT kantarjianhagop s119combinationofminihypercvdandinotuzumabinofollowedbyblinatumomabblinaconsolidationinpatientswithrelapsedrefractoryrracutelymphoblasticleukemiaallaphaseiitrial |